Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory Primary Mediastinal B-Cell Lymphoma
Authors
- Jacopo Mariotti (ORCID: https://orcid.org/0000-0001-6528-9296)
- Monica Balzarotti (ORCID: https://orcid.org/0000-0003-4666-5115)
- Chiara De Philippis (ORCID: https://orcid.org/0000-0002-7738-997X)
- Ciro Maria Improta
- Stéfania Bramanti (ORCID: https://orcid.org/0000-0002-4117-7991)
- Daniele Mannina (ORCID: https://orcid.org/0000-0002-1378-6896)
- Daniela Taurino (ORCID: https://orcid.org/0009-0009-0276-8295)
- Barbara Sarina (ORCID: https://orcid.org/0000-0001-8138-7988)
- Armando Santoro (ORCID: https://orcid.org/0000-0003-1709-9492)
Institutions
- Humanitas University (IT)
- IRCCS Humanitas Research Hospital (IT)